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Abstract
Background: Lung cancer is one of the most common malignant neoplasms worldwide and has a high mortality
rate. To enable individualized therapy regimens, a better understanding of the molecular tumor biology has still to
be elucidated. The expression of the cell surface protein CD24 has already been claimed to be associated with
shorter patient survival in non-small cell lung cancer (NSCLC), however, the prognostic value and applicability of
CD24 immunostaining in paraffin embedded tissue specimens has been questioned due to the recent
acknowledgement of restricted epitope specificity of the commonly used antibody SN3b.
Methods: A cohort of 137 primary NSCLC cases was immunostained with a novel CD24 antibody (clone SWA11),
which specifically recognizes the CD24 protein core and the resulting expression data were compared with
expression profiles based on the monoclonal antibody SN3b. Furthermore, expression data were correlated to
clinico-pathological parameters. Univariate and multivariate survival analyses were conducted with Kaplan Meier
estimates and Cox regression, respectively.
Results: CD24 positivity was found in 34 % resp. 21 % (SN3b) of NSCLC with a membranous and/or cytoplasmic
staining pattern. Kaplan-Meier analyses revealed that membranous, but not cytoplasmic CD24 expression (clone
SWA11) was associated with lympho-nodular spread and shorter overall survival times (both p < 0.05). CD24
expression established by SN3b antibodies did not reveal significant clinicopathological correlations with overall
survival, neither for cytoplasmic nor membranous CD24 staining.
Conclusions: Membranous CD24 immunoreactivity, as detected with antibody clone SWA11 may serve as a
prognostic factor for lymphonodular spread and poorer overall survival. Furthermore, these results corroborate the
importance of a careful distinction between membranous and cytoplasmic localisation, if CD24 is to be considered
as a potential prognostic biomarker.
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Background
Lung cancer is a major cause of carcinoma related death,
being responsible for 17.8 % of all cancer deaths and ac-
counting for more than a million deaths worldwide per
year [1]. Despite intense studies to improve therapy op-
tions, its prognosis has remained poor with a 5-year
overall survival rate of less than 15 % [2].
In the past decade, the largest subgroup of lung cancer,
i.e. non-small cell lung cancer (NSCLC), has been sub-
jected to exerted research for a better understanding of
the underlying molecular biology of lung cancer. More
than ten years ago, CD24 has already been suggested as a
novel and promising biomarker for carcinoma progression
in NSCLC [3] and several groups have confirmed this
finding on protein and transcript level [2, 4]. CD24 is a
highly glycosylated protein, that binds to the cell surface
through a GPI (glycosyl-phosphatidylinositol)-anchor and
functions as a cell adhesion molecule and is involved in
cell-cell-interaction via its P-selectin binding site [5].
CD24 has been found to be expressed by pre-B-lym-
phocytes [5]. It is assumed that CD24-positive cells can at-
tach more easily to platelets and activated endothelial cells
[6, 7]. Notably, CD24 has also been observed in many hu-
man carcinomas, such as ovarian cancer, renal cell cancer,
breast cancer and NSCLC [3, 8–12]. In epithelial ovarian
cancer high scores of cytoplasmic CD24 were highly pre-
dictive of shorter patient survival times (mean 97.8 vs.
36.5 months), whereas membranous CD24 expression
seemed to have no influence on survival times. Interest-
ingly, CD24 positivity (membranous or cytoplasmic) of
prostate cancer samples was significantly associated to
younger patient age and higher pT stages and a higher 3-
year prostate-specific antigen (PSA) relapse rate compared
with CD24-negative tumours.
In patients with gallbladder carcinoma, tumors with
up-regulation of CD24 revealed lymph node metastasis
and lymphovascular invasion more frequently. Moreover,
up-regulation of CD24 tended to show deeper invasion
depth and higher TNM stage [13]. Together, these find-
ings support CD24 as a prognostic marker for carcinoma
progression and poorer survival.
Despite these intriguing findings, major concerns re-
garding a lack of epitope specificity of the commonly
used monoclonal antibody SN3b have been raised [14].
Recent findings indicate that the mAb (monoclonal anti-
body) SN3b does not bind to the protein core itself, but
binds to a glycan structure that decorates the CD24 mol-
ecule. On the one hand, this motif is not present on all
forms of CD24 and—on the other hand—it can be
present in other epitopes irrespective of CD24 [14].
These limitations underline the need for more specific
CD24 antibodies, such as the mAb SWA11 antibody that
has been suggested to be more specific as it binds to the
protein core [14].
As CD24 is a promising biomarker for the risk assess-
ment of disease progression, the goal of the present
study was to investigate CD24 expression in NSCLC
using the novel, more specific monoclonal antibody
(mAb) SWA11. Special emphasis was put on the com-
parison of SN3b- and SWA11-mediated CD24 detection
regarding a) the subcellular distribution of CD24 expres-
sion (i.e. membranous versus cytoplasmic expression)
and b) its correlation with various clinicopathological
features including patient survival times.
Methods
Patient characteristics/ tumor samples
A cohort of 137 primary NSCLC patients, who had under-
gone surgery between 1995 and 2009 and who were all di-
agnosed in the Institute of Pathology, University of Bonn,
was compiled. Tumor samples were available as formalin-
fixed, paraffin-embedded tissue. According to the current
WHO classification the NSCLC were classified as adeno-
carcinoma (AC) (n = 102) or squamous cell carcinoma
(SCC) (n = 35). The male:female ratio (5:2) and mean age
at diagnosis (64y; SD +/− 9y; range 24–86y) in our cohort
was in accordance with the published epidemiologic dis-
tribution [1] (Table 1). No neoadjuvant radiotherapy or
chemotherapy were applied before surgery. All cases were
subjected to a central review based on the current WHO
guidelines [1].
Table 1 Clinicopathological characteristics of the NSCLC cohort
AC SCC
N (%) N (%)
Tumour stage (pT)
1 29 (21.2 %) 5 (3.6)
2 51 (37.2 %) 23 (16.8 %)
3 6 (4.4 %) 6 (4.4 %)
4 1 (0.7 %) 0 (0 %)
Nodal Status (pN) 0 37 (27.0 %) 15 (10.9 %)
1 15 (10.9 %) 9 (6.6 %)
2 14 (10.2 %) 3 (2.2 %)
3 1 (0.7 %) 0 (0.0 %)
Grading (G) 1 5 (3.6 %) 0 (0.0 %)
2 41 (29.9 %) 16 (11.6 %)
3 44 (32.1 %) 17 (12.4 %)
Mean age at surgery 64,2 64,56
(median age) (65) (67)
Sex (m:w) 68:34 30:5
Median OS (months) 52 24
(SD; 95 % CI [months]) (±23.7; 5.5– 98.5) (± 12.8;0.0– 49.0)
SD standard deviation; CI confidence interval; n number of cases; OS
overall survival
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Ethics statement
This study was accomplished under the consent of the
independent ethics committee of the University of Bonn
(approval number 188/14).
Tissue microarray (TMA) assembly
For construction of the tissue microarrays, suitable areas
for extraction of tissue were selected and marked on
haematoxylin-eosin (HE) specimen slides. A senior path-
ologist conducted the microscopic selection of suitable
areas. The selected areas were then punched out of the
corresponding paraffin donor block and inserted into
the recipient block. The tissue arrayer (LD 120 Sm5-x)
was purchased from Alphalys, Paris, France. All punch
diameters were 0.8 mm (corresponding to an spot area
of 0.79 mm2). Each case was represented by 3 tumor
samples and 1 peritumoral non-neoplastic tissue sample.
Immunohistochemistry
Formalin-fixed TMA sections were freshly cut (2–3 μm)
and mounted on superfrost specimen slides (Thermo
Fisher). Next, dewaxing was carried out with xylene and
the tissue sections were gradually rehydrated. Antigen
retrieval was achieved by pressure cooking in the auto-
clave at pH6 and under hyperfrequency wave of 360 W
at 125 °C for 8 min. MAb SWA11 was diluted 1:100 and
SN3b was diluted 1:50, each using a modul buffer from
Medac (TA-250-PM). The immunohistochemical reac-
tion was visualized using the detection system C-DPVB
500 HRP by Medac (all procedures were conducted ac-
cording to the instructions of the manufacturer).
Positive controls, consisting of tissue samples with
known positivity for the antibody, and negative controls
(i.e. reactions lacking the primary antibody), were per-
formed in parallel for each TMA slide. Expression inten-
sity was examined in a semiquantitative manner (score
0: no staining, score 1: weak, score 2: moderate and
score 3: strong staining). For statistical analyses, cases
with moderate to strong expression were bundled in a
‘high expression’ and cases with negative or weak ex-
pression in a ‘low expression’ group.
Follow-up analyses
Follow-up data were available in 93 cases. Patients suf-
fered from primary malignant tumors of the lung and
were subjected to surgical resection or diagnostic sam-
pling between 1995 and 2009 Cases with sufficient avail-
ability of formalin-fixed, paraffin-embedded tissue entered
the cohort. Survival data were obtained by the analysis of
surgical and oncological medical reports as well as written
request for data of the local registration offices. The sur-
vival time was defined as the time period between the date
of surgery and the date of death resp. the date of the docu-
mentation as “still alive” at the last available time point.
The median survival of AC cases was 52 months (SD 23.7;
95 % CI: 5.5–98.5; n = 67), compared to SCC with
24 months (SD 12; 95 % CI: 0–49.0; n = 26). 62 patients
died within the follow-up period. The remaining 31 pa-
tients were documentes as “still alive” at the last available
time point. Only in 13 patients without documentation of
death the follow-up period was less than 60 months.
Statistical analysis
For statistical analysis the SPSS software v. 21.0 was used.
For evaluation of the correlation between expression of
CD24 and clinicopathological parameters Fisher’s exact test
was used. Univariate survival analysis included Kaplan-
Meier-analyses with log-rank testing for the estimation of
differences in survival times. For multivariate survival ana-
lysis, the Cox regression model was used. All cutoff values
of significance were set p < 0.05 with two-sided testing.
Results
Immunohistochemical detection of CD24 expression
using clone SWA11 and SN3b
Using the mAb SWA11, 47 of 137 (34.3 %) NSCLC re-
vealed CD24 expression (either cytoplasmic or mem-
branous) (Table 2). CD24 expression was observed more
frequently in adenocarcinomas (AC) than in squamous
cell carcinomas (SCC). In AC cytoplasmic expression
was observed more frequently than membranous expres-
sion. In SCC, both cyptoplasmic and membranous ex-
pression was rare. Normal lung parenchyma (i.e. alveolar
surface cells) showed no expression of CD24. Bronchial
epithelium showed a strong membranous and cytoplas-
mic staining of the brush border (Fig. 1).
Using the mAb SN3b, 29 of 137 (21.2 %) NSCLC revealed
CD24 expression (either cytoplasmic or membranous)
(Table 2). As above, CD24 expression was observed more
frequently in adenocarcinomas (AC) than in squamous cell
carcinomas (SCC). However, in contrast to mAb SWA11
cytoplasmic expression was observed less frequently than
membranous expression in AC. In SCC, both cytoplasmic
and membranous expression was rare. Normal lung paren-
chyma (i.e. alveolar surface cells) showed a distinct mem-
branous immunoreactivity. Bronchial epithelium revealed
both membranous and cytoplasmic staining of CD24.
Correlation between SWA11 and SN3b: As SWA11 and
SN3b detect different epitopes, we evaluated the correlation
of the immunohistochemical staining patterns. Of 132
NSCLC specimens with matched expression data, only 9
specimens (6.8 %) revealed a concordant CD24 expression.
Of these cases, 4 cases revealed a concordant cytoplasmic
staining and another 5 cases revealed a concordant
membranous CD24 expression. Statistically, no significant
correlation between the two mAb could be observed (cc =
−0.63, p = 0.470; Fisher’s exact test p = 0.665). The correl-
ation of cytoplasmic and membranous expression (for each
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antibody) was as follows: cc = 0.475 (p < 0.05) for SWA11
(n = 108) and cc = 0.140 (p = 0.11) for SN3b (n = 103).
Survival analyses
Recent studies indicate that CD24 expression is associated
with tumor progression and poorer survival rates. Therefore,
we performed follow up analyses with a special emphasis on
1) the prognostic value of mAb SWA11 in dependence on
subcellular staining characteristics and 2) the prognostic
values of different clinicopathological parameters:
Prognostic value of CD24 in Kaplan Meier Analyses
Only membranous CD24 (SWA11) staining revealed
significantly poorer survival rates (median overall survival
21 vs. 52 months; p = 0.005) as illustrated in Fig. 2. In con-
trast, cytoplasmic CD24 (SWA11) staining did not affect
the survival rates (median OS 34 vs. 35 months; p =
0.884) (Table 3). When stratifying the cohort into SCC (n =
35) and AC (n = 102) in Kaplan Meier analyses, mem-
branous CD24 (SWA11) expression did not affect patients’
survival, neither in SCC (p = 0.243) nor AC (p = 0.135)
(Table 3), probably due to the small number of observations
(Fisher exact test: p > 0.05). After stratification for AC sub-
types, membranous CD24 expression (SWA11) showed a
tendency towards an association with poorer survival in aci-
nar subtype AC, but failed significance (p = 0.328).
CD24 immunoreactivity using the mAb SN3b was not
associated with patients’ survival: neither the membranous
A B DC
E F G H
Fig 1 The immunohistochemical characterization reveals membranous and/or cytoplasmic CD24 (mAb SWA11) expression. Strong cytoplasmic
CD24 expression is found in a proportion of both AC (a) and SCC (b, d) specimens. Membranous CD24 expression can be pronounced with only
scant or even absent cytoplasmic staining as shown in the AC (c). Also, both membranous and cytoplasmic CD24 detection can be found in
some instances (d), the insert is showing the corresponding squamous carcinoma in-situ with membranous staining. Simultaneous membranous
and cytoplasmic CD24 expression is also found in AC specimens (e, f). In normal tissue, alveolar epithelial cells do not express CD24 (g), whereas
CD24 staining is found at the apical cell membrane of bronchial respiratory epithelia (h)
Table 2 Cytoplasmic and membranous expression of CD24
SWA11 (mAb clone) SN3b (mAB clone)
AC SCC AC SCC
Cytoplasmic N (%) N (%) Cytoplasmic N (%) N (%)
0 45 (32.6 %) 19 (13.8 %) 0 76 (55.1 %) 31 (22.5 %)
1 22 (15.9 %) 8 (5.8 %) 1 12 (8.7 %) 1 (0.7 %)
2 17 (12.3 %) 4 (2.9 %) 2 7 (5.1 %) 2 (1.4 %)
3 18 (13.0 %) 4 (2.9 %) 3 1 (0.7 %) 0 (0 %)
AC SCC AC SCC
Membranous N (%) N (%) Membranous N (%) N (%)
0 68 (49.3 %) 21 (15.2 %) 0 64 (46.4 %) 30 (21.7 %)
1 21 (15.2 %) 5 (3.6 %) 1 10 (7.2 %) 2 (1.4 %)
2 8 (5.8 %) 4 (2.9 %) 2 12 (8.7 %) 2 1.4 %)
3 5 (3.6 %) 5 (3.6 %) 3 10 (7.2 %) 0 (0 %)
Staining intensities are determined as follows:
0: negative or equivocal, 1: weak, 2: moderate and 3: strong CD24 staining
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Fig 2 Survival analysis. Kaplan-Meier curves according to SWA11 expression. Cases with moderate to strong expression were bundled in a ‘high
expression’ and cases with negative or weak expression in a ‘low expression’ group. Membranous expression of CD24 detected by SWA11 proved
to be an independent marker for shorter survival times in NSCLC (p = 0.005)
Table 3 Univariate survival analysis
SWA11 No. of
cases
Mean survival time Median survival time p-value
(months +/− s.e.) (months +/− s.e.)
Mem CD24
Negative 76 84.833 +/− 10.395 52.000 +/− 27.030 0.005
Positive 16 27.925 +/− 6.379 21.000 +/− 4.000
Cyto CD24
Negative 66 75.209 +/− 10.577 35.000 +/− 12.422 0.884
Positive 26 60.540 +/− 11.551 34.000 +/− 12.196
Total CD24
Negative 64 76.972 +/− 10.841 35.000 +/− 13.726 0.633
Positive 28 57.535 +/− 10.895 34.000 +/− 9.303
SCC
Mem CD24 negative 16 52.063 +/− 14.668 16.000 +/− 16.000 0.243
Mem CD24 positive 7 21.571 +/− 7.201 24.000 +/− 23.568
AC
Mem CD24 negative 59 88.953 +/− 11.631 56.000 +/− 22.885 0.135
Mem CD24 positive 8 39.167 +/− 11.674 21.000 +/− 8.485
pN0 31 103.641 +/− 14.940 93.000 +/− 28.224 0.012
pN1+ 30 54.911 +/− 10.646 26.000 +/− 0.983
Majores et al. BMC Clinical Pathology  (2015) 15:19 Page 5 of 8
staining pattern (p = 0.9), nor the cytoplasmic staining pat-
tern (p = 0.924) revealed any significant effect on the over-
all survival.
Prognostic values of the clinicopathological parameters
To further verify the prognostic values of different clini-
copathological parameters, Cox regression analyses were
conducted. As expected, positive nodal status (pN > 0)
(p = 0.003) and disease stage (pT) (p = 0.006) were asso-
ciated with poorer survival rates in univariate analyses
(Table 4). Also, membranous CD24 (SWA11) positivity
(p = 0.007) and histological tumour type (p < 0.001)
showed a correlation with poorer survival rates. Subject-
ing the first three criteria to multivariate analyses, only
membranous CD24 (SWA11) positivity (p = 0.014) and
positive nodal status (p = 0.027), but not disease stage
(p = 0.185) maintained independent factors for poorer
overall survival (Table 5). In an extended multivariate Cox
regression model with inclusion of tumour histology,
membranous CD24 expression failed significance, but still
showed a trend towards an association with shortened
survival times (p = 0.094). CD24 expression using the
mAb SN3b revealed no association with survival charac-
teristics, neither for total (membranous or cytoplasmic)
expression, nor for membranous or cytoplasmic expres-
sion alone (all p > 0.05, data not shown).
Discussion
In the present study, we have analyzed immunohisto-
chemical staining characteristics and the prognostic
value of CD24 expression in NSCLC with a special em-
phasis on the comparison of the CD24 antibodies
SWA11 and SN3b. The most important result of our
study is that the prognostic relevance of CD24 is critic-
ally dependent on the careful consideration of sub-
cellular compartments and the epitope specificity of the
antibody used.
Overall, about one third of the NSCLC cohort revealed
a significant CD24 expression (either cytoplasmic or
membranous). These results are in line with the findings
of other studies. In another NSCLC cohort, CD24
(SN3b) expression was found in 33 % of the samples (87
of 267 cases) [2]. Consistent with those results, we have
found similar rates of high CD24 expression levels (35 %
of the cases) for SWA11. Originally, we would have
expected lower rates than those found by Lee et al, as
they used the antibody SN3b, that also recognizes yet
unidentified other glycoproteins next to CD24. Further-
more, they used whole mount sections instead of tissue
microarrays. A possible explanation for rather equal de-
tection rates would be the fact that it has been demon-
strated that the epitope recognized by SN3b is indeed
present in CD24, but is not found in all glycoforms of
CD24 [14]. In contrast to the commonly used mAb
SN3b, mAb SWA11 binds to the protein core of CD24
and does not depict other glycan moieties next to CD24.
The protein core of CD24 is linear, consisting of the
amino acid sequence leucine-proline-alanine (LAP) next
to a glycosyl-phosphatidylinositol anchor [15].
CD24 expression has been associated with disease pro-
gression and cancer-related death in the majority of ma-
lignant tumors [2, 3, 16, 17], although a caveat to these
data is that most of these studies are based on the sup-
posedly less specific CD24 clone SN3b. Lee et al demon-
strated a significant association between CD24-high
expression (SN3b) and shorter patient survival times.
Furthermore, Lee and colleagues and ourselves in former
studies referred the results to cytoplasmic CD24 expres-
sion [2, 3].
In invasive ovarian carcinoma, patients carrying tumors
with cytoplasmic CD24 expression showed a significantly
shorter mean survival time of 37 months versus patients
with tumors without cytoplasmic expression of CD24
(98 months) [16]. Also in NSCLC, expression of CD24 has
been claimed to be an independent prognostic marker of
shorter patient survival times, especially in AC [3].
Recently, CD24 expression has been addressed as a pu-
tative stem cell marker in NSCLC [10]. In that context
particular attention has to be paid to the co-expression of
CD44. Sterlacci et al. demonstrated that the phenotype
CD24−/CD44+ did not show a significant difference in
overall survival for the entire NSCLC cohort when com-
pared with the CD24+/CD44 −population. However, when
stratified according to histology, AC displaying the puta-
tive cancer stem cell (CSC) signature CD24−/CD44+ had
a significantly shorter overall survival than CD24+/CD44−
AC. However, these findings could not be ascertained as
an independent factor, when calculated by multivariable
analysis [10]. Since the overwhelming evidence of the pro-
tumorigenic properties of CD24 is independent of the
CD24low/CD44-high stem cell definition, we focused on
Table 4 Univariate survival analysis according to the Cox
regression model (mAb SWA11)
Beta HR (hazard ratio) 95 % CI of HR P-value
SWA11 mem all 0.856 2.353 1.268–4.364 0.007
pN 0.963 2.620 1.389–4.943 0.003
pT 0.844 2.325 1.279–4.224 0.006
Tumour type 0.975 2.651 1.999–3.517 0.000
Table 5 Multivariate survival analysis according to the Cox
regression model (mAb SWA11)
Beta HR (hazard ratio) 95 % CI of HR P-value
SWA11 mem all 0.944 2.571 1.211–5.458 0.014
pN 0.737 2.091 1.087–4.021 0.027
pT 0.587 1.799 0.755–4.283 0.185
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CD24 expression alone and did not include CD44 expres-
sion data in the present study.
Our results are only partly consistent with the pub-
lished data. We were able to demonstrate that mem-
branous staining pattern (using the mAb SWA11) was
associated with a poorer overall survival and we revealed
an increased risk of lymphonodular spread in the sub-
group of CD24-high tumors, being in accordance with
the published data. Nonetheless, our results are also par-
tially conflicting with previous immunohistochemical
data, as we could not confirm a significant correlation
with patient survival for cytoplasmic expression of
CD24, neither for SWA11 nor for SN3b.
The underlying biological mechanisms of CD24 pro-
moted tumor progression are still incompletely charac-
terized, although a growing number of studies have
contributed to our comprehension [5–7, 17–20]. Expres-
sion of CD24 may provide an enhanced capability of
tumor cells to adhere to activated endothelial cells medi-
ated by its P-selectin binding site [5] or alter cellular sig-
naling [21]. Aigner and colleagues showed that CD24
functions as a ligand for P-Selectin under physiological
flow conditions, using a plate flow chamber assay. In
their study, CD24 proved to be necessary for mediation
of rolling on P-Selectin, as low expression levels or
cleavage of CD24 resulted in inhibition of attachment
and rolling, in a breast carcinoma cell line [6]. The pre-
cise mechanisms of ligand binding have still to be eluci-
dated. In particular, CD24 does not contain the sulfated
tyrosine residue of the P-Selectin glycoprotein ligand 1
(PSGL-1), i.e. another P-Selectin ligand [22]. Another
mechanism of CD24 binding focuses on the observed as-
sociation of CD24 with the sulfate-containing epitope
HNK-1 which is also recognized by P-Selectin. This ob-
servation may lead to the assumption that HNK-1 medi-
ates CD24 binding [7]. Enhanced disease progression as
a result of metastatic spread with poorer survival rates
may therefore be reasonable [6, 7]. As known, cells of
hematogenously metastasizing tumours attach to plate-
lets in the bloodstream [23–25]. Activated platelets ex-
press P-Selectin. Therefore, CD24-positive cells probably
attach to activated platelets, containing P-Selectin on
their surface, at the point, when the primary tumour in-
vades into the vascular system [6]. Moreover, CD24-
mediated tumor propagation has also been associated
with an increase of local invasiveness: CD24 mediated
invasion of cancer cells has been hypothesized as a result
of increased contractile forces as indicated by the find-
ings of A125 human lung cancer cells with different
CD24 expression levels using CD24-high and CD24-low
transfectants in three-dimensional extracellular matrix
(ECM) invasion assays [19]. The percentage of invasive
cells and their invasion depth was increased in CD24-
high cells compared with CD24-low cells. Conversely,
knockdown of CD24 and of the ß1-integrin subunit in
CD24-high cells decreased their invasiveness, indicating
that the increased invasiveness is CD24- and ß1-integrin
subunit-dependent [19]. Interestingly, besides acting as a
ligand for P-Selectin, recently it has been proven that
CD24 expression also indirectly stimulates cell adhesion
to fibronectin, collagens 1 and 4, and laminin through
activation of α3β1 and α4β1 integrin activity. Sleeman
and colleagues have reported that β1 integrins colocalize
focally with CD24. This suggests a direct interaction be-
tween CD24 and β1-containing integrins. In their study
they show that CD24 interacts with c-scr, leading to
stabilization of the kinase-active form of c-scr, which is
necessary for sufficient activation of integrin adhesion to
extracellular matrix components such as fibronectin.
Thus, CD24 mediates cell adhesion in a P-Selectin
dependent and a P-Selectin independent manner [26].
Next to its influence on cell adhesion, metastasis and on
invasion, CD24 also serves as a mediator of proliferation.
Apparently, a depletion of CD24 by siRNA leads to a
significant decrease of cell numbers in several cell lines
as well as to a reduction of their clonogenicity [17].
These experimental results provide a functionally well
compatible explanation for the observed clinicopatho-
logical correlation of CD24 expression and poorer over-
all survival resp. increased occurrence of lymphonodular
spread in our study.
Notably, CD24 may also provide a promising target for
individualized therapy strategies beyond the scope of
prediction. For example, CD24 specific antibodies have
been applied in the treatment of the transplantation as-
sociated B-cell proliferative syndrome [18]. Moreover,
mAb SWA11 has recently been shown to have a benefi-
cial effect on anti-cancer treatment when used as
addition to gemcitabine treatment in an A549 lung can-
cer model [20]. Pretreatment with mAb SWA11 led to a
significant retardation of carcinoma growth compared to
monotherapy with gemcitabine, which was attributed to
faster internalisation of tumour antigen-bound thera-
peutic antibodies and alterations in the intratumoural
cytokine milieu. Increased levels of intratumoural che-
moattractants such as CXCL9/MIG and CCL2/MCP-1
were observed, in accordance to a heightened infiltration
of xenografts by macrophages, possibly gained through
the involvement of the antibody-dependent cell-mediated
cytotoxicity. [20]
Some parts of our results, however, are conflicting
with previous data, as we could not reproduce a signifi-
cant correlation with patient survival for cytoplasmic ex-
pression of CD24 for SWA11. Vice versa, we revealed
that only the membranous staining pattern was indica-
tive for poorer overall survival (p = 0.007). As a minimal
discordance to findings of former NSCLC studies [2, 3],
our SWA11 based study could not confirm an especially
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relevant prognostic value of CD24 for pulmonary adeno-
carcinomas. Still, this study demonstrates a small trend
towards a subtype-dependent prognostic relevance of
membranous CD24 expression. Larger cohorts will be
necessary for a more substantial statistical power con-
cerning its prognostic relevance for AC.
Conclusions
In summary, our data provides further evidence for
CD24 as a functionally relevant biomarker with prognos-
tic significance in NSCLC. Methodically, our results
underline the necessity to choose a specific antibody and
to carefully consider subcellular staining differences of
CD24 for robust prognostic conclusions. The use of
mAb SWA11 should be favoured for a more specific de-
tection of the cell surface protein CD24 as it allows a
good visual distinction between membranous and cyto-
plasmic staining. A distinction between strongly and less
strongly stained cells may be challenging in the light of
laboratory-specific variations as well as inevitable inter-
observer variability. Further studies should clarify, if an
adjuvant therapeutic use of CD24 antibodies may have
an additive value in cancer treatment.
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